SER recommendations on the use of biological drugs in primary Sjogren's syndrome
Objective: To formulate SER recommendations for the use of biological agents in primary Sjogren's syndrome (pSS). Methods: Relevant clinical research questions were identified on the use of biological agents in pSS. The clinical questions were reformulated into 4 PICO questions. A search strate...
| Autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p7247 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/7247 |
| Access Level: | acceso abierto |
| Palabra clave: | Sjogren's syndrome Biological therapy Etanercept Infliximab Rituximab Belimumab Abatacept Tocilizumab Spanish Society of Rheumatology Recommendations |
| id |
ES_507a22fa4fc3ecdced8b9626fa8bc124 |
|---|---|
| oai_identifier_str |
oai:fisabio.fundanetsuite.com:p7247 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
SER recommendations on the use of biological drugs in primary Sjogren's syndromeAndréu Sánchez JLFernández Castro MDel Campo Fontecha PDCorominas HNarváez García FJGómez de Salazar JRRua-Figueroa ÍAbad Hernández MÁÁlvarez Rivas MNMontes JDPFrancisco Hernández FMGantes Pedraza MÁGreco Merino MGHernández MVNavarro Compán MVSolarte JAPRomero Bueno FIPark HSSivera Mascaró FSjogren's syndromeBiological therapyEtanerceptInfliximabRituximabBelimumabAbataceptTocilizumabSpanish Society of RheumatologyRecommendationsObjective: To formulate SER recommendations for the use of biological agents in primary Sjogren's syndrome (pSS). Methods: Relevant clinical research questions were identified on the use of biological agents in pSS. The clinical questions were reformulated into 4 PICO questions. A search strategy was designed and a review of the scientific evidence of studies published until May 2017 was carried out. The scientific evidence available was systematically reviewed. The overall level of scientific evidence was assessed using the SIGN evidence levels. After that, specific recommendations were made. Results: Rituximab is recommended as the biological agent of choice for extraglandular manifestations refractory to conventional treatment. The use of anti-TNF agents is discouraged. The scientific evidence with belimumab and abatacept is scarce, so they should be considered only in cases refractory to rituximab. Conclusions: Rituximab is the biological agent of choice in severe extraglandular manifestations of pSS. Belimumab or abatacept may be useful in selected cases. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.ELSEVIER ESPANA SLU2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/7247Reumatologia ClinicaISSN: 1699258XISSNe: 18851398reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p72472026-06-11T12:45:17Z |
| dc.title.none.fl_str_mv |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| title |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| spellingShingle |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome Andréu Sánchez JL Sjogren's syndrome Biological therapy Etanercept Infliximab Rituximab Belimumab Abatacept Tocilizumab Spanish Society of Rheumatology Recommendations |
| title_short |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| title_full |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| title_fullStr |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| title_full_unstemmed |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| title_sort |
SER recommendations on the use of biological drugs in primary Sjogren's syndrome |
| dc.creator.none.fl_str_mv |
Andréu Sánchez JL Fernández Castro M Del Campo Fontecha PD Corominas H Narváez García FJ Gómez de Salazar JR Rua-Figueroa Í Abad Hernández MÁ Álvarez Rivas MN Montes JDP Francisco Hernández FM Gantes Pedraza MÁ Greco Merino MG Hernández MV Navarro Compán MV Solarte JAP Romero Bueno FI Park HS Sivera Mascaró F |
| author |
Andréu Sánchez JL |
| author_facet |
Andréu Sánchez JL Fernández Castro M Del Campo Fontecha PD Corominas H Narváez García FJ Gómez de Salazar JR Rua-Figueroa Í Abad Hernández MÁ Álvarez Rivas MN Montes JDP Francisco Hernández FM Gantes Pedraza MÁ Greco Merino MG Hernández MV Navarro Compán MV Solarte JAP Romero Bueno FI Park HS Sivera Mascaró F |
| author_role |
author |
| author2 |
Fernández Castro M Del Campo Fontecha PD Corominas H Narváez García FJ Gómez de Salazar JR Rua-Figueroa Í Abad Hernández MÁ Álvarez Rivas MN Montes JDP Francisco Hernández FM Gantes Pedraza MÁ Greco Merino MG Hernández MV Navarro Compán MV Solarte JAP Romero Bueno FI Park HS Sivera Mascaró F |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Sjogren's syndrome Biological therapy Etanercept Infliximab Rituximab Belimumab Abatacept Tocilizumab Spanish Society of Rheumatology Recommendations |
| topic |
Sjogren's syndrome Biological therapy Etanercept Infliximab Rituximab Belimumab Abatacept Tocilizumab Spanish Society of Rheumatology Recommendations |
| description |
Objective: To formulate SER recommendations for the use of biological agents in primary Sjogren's syndrome (pSS). Methods: Relevant clinical research questions were identified on the use of biological agents in pSS. The clinical questions were reformulated into 4 PICO questions. A search strategy was designed and a review of the scientific evidence of studies published until May 2017 was carried out. The scientific evidence available was systematically reviewed. The overall level of scientific evidence was assessed using the SIGN evidence levels. After that, specific recommendations were made. Results: Rituximab is recommended as the biological agent of choice for extraglandular manifestations refractory to conventional treatment. The use of anti-TNF agents is discouraged. The scientific evidence with belimumab and abatacept is scarce, so they should be considered only in cases refractory to rituximab. Conclusions: Rituximab is the biological agent of choice in severe extraglandular manifestations of pSS. Belimumab or abatacept may be useful in selected cases. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2019 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://fisabio.portalinvestigacion.com/publicaciones/7247 |
| url |
https://fisabio.portalinvestigacion.com/publicaciones/7247 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
ELSEVIER ESPANA SLU |
| publisher.none.fl_str_mv |
ELSEVIER ESPANA SLU |
| dc.source.none.fl_str_mv |
Reumatologia Clinica ISSN: 1699258X ISSNe: 18851398 reponame:r-FISABIO. Repositorio Institucional de Producción Científica instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| instname_str |
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| reponame_str |
r-FISABIO. Repositorio Institucional de Producción Científica |
| collection |
r-FISABIO. Repositorio Institucional de Producción Científica |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869407893146566656 |
| score |
15,81155 |